10 results about "Pancreatic A Cells" patented technology

The present disclosure relates to a method of generating pancreatic lineage cells, e.g. islet-like cell aggregates comprising pancreatic beta cells, comprising the steps of providing a single cell suspension of a population of endocrine progenitor cells (EP), allowing the EP cells in the single cell suspension to form 3D structures, and culturing the cells under conditions allowing differentiation into pancreatic mono-hormonal beta cells. The present disclosure also relates to islet-like cell aggregates obtainable by said method and their medical use.

The present disclosure provides a use of a substance targeting BRD4 in the preparation of a product related to diabetes. In the present disclosure, it is found that the expression of BRD4 in human diabetic beta cells is significantly reduced, and BRD4 plays an important role in maintaining beta cell maturation and differentiation, and long-term and acute BRD4 deficiency can lead to reduced insulin secretion and down-regulation of differentiation markers, highlighting the key role of BRD4 in pancreatic beta cells, providing a target BRD4 that has a significant impact on diabetes, so that substances targeting BRD4 can help to assess the susceptibility of diabetes, screening, prevention, intervention and treatment of diabetes.

An amplifying method of pancreatic cells is provided. The amplifying method includes performing digestion, resuspension, discontinuous density gradient centrifugation treatment and amplifying treatment sequentially. The mammalian pancreatic duct is used as the source of pancreatic precursor-like cells in the amplifying method, and islet cells and acinar cells in the cell clusters obtained by the discontinuous density gradient centrifugation treatment are removed. It is beneficial to improve the yield of the pancreatic precursor-like cells availably, and avoid the ethical restrictions and possible carcinogenic risks caused by using the embryonic stem cells. The amplifying medium used comprises a reprogramming substance composed of several small molecule compounds. It can avoid the risks of non-specific and off-target deletion that are easily caused by the use of the gene-editing methods to change the gene sequence. Also provided is a differentiation method and an application of the pancreatic precursor-like cells obtained by the amplifying method.

The present disclosure provides compositions of stem cell-derived pancreatic islet cells engineered for improved engraftment and methods of use thereof for treating a subject having an insulin deficiency.

Distribution and reception device for a heterogeneous population of pancreatic cells, method and bioreactor The invention relates to a distribution and reception device for a heterogeneous population in size of pancreatic islets, comprising a matrix having a first face opposite a second face, characterized in that the matrix comprises concentric channels centered on a center O, the channels have an opening for receiving pancreatic cells, opening onto the first face, the opening extending over the entire length (L) of the channel, the opening having a width (l) taken according to section Si, the device being configured so that the widths of the opening of two adjacent channels have an equal or increasing value when moving away from the center O and that the widths of the opening of a channel closest to the center O and of a channel furthest from the center O have an increasing value when moving away from the center O.The field of implantable devices, in particular artificial pancreas. Figure for the abstract: Fig.1.

To provide a system and method for predicting insulin resistance and / or a pancreatic β-cell function.SOLUTION: A system disclosed herein uses a machine-learning model to predict insulin resistance and / or a decline in a pancreatic β-cell function of a subject in need thereof based on a feature set extracted from a database. As such, clinicians or the subject can be warned to take necessary actions and adjust a related medical treatment or lifestyle before the subject is diagnosed with diabetes mellitus. A computer-readable medium therefor is also provided.SELECTED DRAWING: Figure 1

The present invention relates to methods and compositions for regulating the migration and activity of type 2 innate lymphoid cells (ILC2) in order to modulate pancreatic glucagon secretion. The activation of sympathetic neuronal pathways innervating the intestine induces a reduction of ILC2 in the small intestine and promotes their rapid accumulation in pancreatic tissue. In the pancreas, the ILC2 secrete IL-5 and IL-13, which act directly on pancreatic α-cells expressing IL-5Rα and IL-13Rα to increase glucagon secretion.

The present invention relates to methods of efficiently generating pancreatic endoderm from human pluripotent stem (PS) cell derived human definitive endoderm. The present invention also relates to pancreatic endoderm cells obtained by the methods of the invention. Finally, the present invention relates to culture medium and composition comprising a RAR antagonist and uses of said RAR antagonist in the induction of pancreatic endoderm cells. The present invention provides a more homogenous and synchronised pancreatic cell population, with increased efficiency.

Provided herein is a composition comprising a functionalized pancreatic extracellular matrix (CP-PAN-ECM) comprising at least one immune checkpoint molecule. Also provided herein is a method of making the composition, and a method of treating diabetes using the composition.